The impact of myelosuppression on quality of life of patients treated with chemotherapy

J Crawford has participated as a scientific advisor for Actimed Therapeutics, Enzychem Lifesciences, Faraday Pharmaceuticals, Jazz Pharmaceuticals, Partner Therapeutics, and Pfizer; participated on publications committees for Amgen, Frensenius Kabi, G1 Therapeutics Inc., LUNGevity Foundation, Pfizer and Spectrum Pharmaceuticals; and participated on data safety monitoring boards for BioAtla, G1 Therapeutics, Inc and NiA Pharmaceuticals. The authors have no other competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript apart from those disclosed.

Comments (0)

No login
gif